Show Notes
Green book, JCVI advises that breastfeeding women should be offered any suitable COVID-19 vaccine.Uploaded 02-09-22https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1098808/Greenbook-chapter-14A-17August2022.pdf(Updated, 17th August, 2022)Summary of the Public Assessment Report. For covid-19 vaccine, Pfizer/BioNTechttps://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/summary-public-assessment-report-for-pfizerbiontech-covid-19-vaccineWomen who are breastfeeding should also not be vaccinated. (Updated, 16th August, 2022)Summary of the Public Assessment ReportAuthorisation for Temporary Supply, COVID-19 mRNA Vaccine BNT162b2 (BNT162b2 RNA) concentrate for solution for injectionDepartment of Health and Social Care (DHSC), Pfizer Limited and BioNTech Manufacturing, GmbHhttps://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/summary-public-assessment-report-for-pfizerbiontech-covid-19-vaccineUpdated, 16th August, 2022Reproductive and developmental toxicityFertility and early embryonic development and embryofoetal developmentA combined fertility and developmental study (including teratogenicity and postnatal investigations) in rats is ongoing.Prenatal and postnatal development, including maternal functionNo such studies have been done.Studies in which the offspring (juvenile animals) are dosed and/or further evaluatedNo such studies have been done.Local toleranceNo such studies have been done. The assessments made as part of the general toxicity study should suffice and a separate study is not needed.Other toxicity studiesNo such studies have been done.Toxicity conclusionsThe absence of reproductive toxicity data is a reflection of the speed of development to first identify and select COVID-19 mRNA Vaccine BNT162b2 for clinical testing and its rapid development to meet the ongoing urgent health need. In principle, a decision on licensing a vaccine could be taken in these circumstances without data from reproductive toxicity studies animals, but there are studies ongoing and these will be provided when available. In the context of supply under Regulation 174, it is considered that sufficient reassurance of safe use of the vaccine in pregnant women cannot be provided at the present time: however, use in women of childbearing potential could be supported,provided healthcare professionals are advised to rule out known or suspected pregnancy prior to vaccination. Women who are breastfeeding should also not be vaccinated. Green book, updated 17th August 2022Specific population groups https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1098808/Greenbook-chapter-14A-17August2022.pdfPregnancy There is no known risk associated with giving inactivated, recombinant viral or bacterial vaccines or toxoids during pregnancy or whilst breastfeeding (Kroger et al, 2013). Developmental and reproductivity testing of the Pfizer BioNTech, Moderna and AstraZeneca vaccines in animals have not raised any concerns. JCVI has therefore advised that women who are pregnant should be recommended to receive primary immunisation, and that pregnancy is considered a clinical risk group for the autumn booster programme. Routine questioning about last menstrual period and/or pregnancy testing is not required before offering the vaccine. Surveillance of the inadvertent administration of COVID-19 vaccines in early pregnancy is being conducted for the UK by the UK Health Security Agency Immunisation and Vaccine Preventable Diseases Division, to whom such cases should be reported.1 This surveillance is being undertaken to document safety in women who unknowingly receive a vaccine in early pregnancyBreas Learn more about your ad choices. Visit megaphone.fm/adchoices
More from Dr. John Campbell
Excess deaths AND long-term sickness dramatically increased in the UK
BA.5, immune escapeUploaded 30-06-22Vaccines and previous infections are protective against severe diseasePercentages of positives that were infected more than 90 days agoProgressively increasingNow, 12 % reinfections3 months ago, 8% reinfections6 months ago, 5% reinfectionshttps://www.youtube.com/watch?v=TwQp3Yc82akR = 1.1Up 27% on the weekUK, 1 in 21Scotland 1 in 15, highest ever ratesYoung people and young adults highestWill go up for a time, summer mixing, festivalsConsistent with ONS datahttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsightsOne week aheadHospital admissions up 37%List of covid symptomsRunny nose, 66%Sore throat, 65%Headache, 64%Persistent cough, 63%Fatigue, 62%Sneezing, 53%Hoarse, 44%Joint pains, 35%Fever, 31%Chills or shivers, 30%Muscle pains 29%Dizzy, 27%Brain fog, 24%Sore eyes, 22%Altered smell, 21%Lower back pain, 22%Swollen glands, 19%Skipped meals, 17%Chest pain, 15%BA.5 is milder than previous variantsStill time off workHospital admissions due to large numbersOfficial data UKhttps://coronavirus.data.gov.ukCoronavirus vaccines should be updated for fallhttps://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-14-15-2022-meeting-announcementFDA advisory committeeDeadline, vaccine formula for October, nowBA.1 vaccine, in human tests for monthsArnold Monto, FDA advisory committeeWe’re being asked, more or less, to have a crystal ball todayNew multi-strain vaccine, original and omicronSome wanted BA.4 and BA.5, others BA.1Moderna, Novavax, Pfizer, each presented data to support their strategyModerna, bivalent, for example, original version + BA.1 variantPfizer BioNTech, only BA.1Pfizer presented mouse data on BA.4 and BA.5Novavax’s vaccine (not yet authorized in United States), additional doses of its existing vaccine could be protective? will these new formulations apply to children without testing? local or globalLyme disease Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2 Uploaded 07-08-21https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(21)00198-X/fulltextPDFhttps://www.thelancet.com/action/showPdf?pii=S2352-4642%2821%2900198-Xhttps://www.bbc.co.uk/news/health-58071898BackgroundInfection is usually asymptomatic or causes a mild illness of short durationPersistent illness has been reportedTo determine illness duration and characteristics in symptomatic UK school-aged childrenCOVID Symptom StudyMethodsProspective cohort studyAged children 5–17 yearsReported by an adult proxyIllness duration and symptom prevalence, for children testing positiveData from symptomatic children testing negative for SARS-CoV-2, matched 1:1 for age, gender, and week of testing, were also assessedFindings, Children aged 5–17 March 24, 2020 to Feb 22, 2021N = 258,790 Valid test result, n = 75,529 had valid test results for SARS-CoV-2.Positive test result, n = 1,734 children(588 younger and 1,146 older children)And had a calculable illness durationThe most common symptomsHeadache 1,079 (62·2%) of 1734 childrenFatigue 954 (55·0%) of 1734 children)Median illness duration Children testing positive, 6 days Children testing negative, 3 days Illness duration associated with age(Spearman's rank-order rs 0·19, p less than 0·0001)Median illness duration was longer for older childrenOlder children, 12 to 17 years, 7 daysYounger children, 5 to 11 years, 5 daysIllness duration of at least 28 days77 (4·4%) of 1,734 children59 (5·1%) of 1,146 older children18 (3·1%) of 588 younger children(p=0·046)After day 28, median 2 symptomsFirst week of illness, median 6 symptomsCommonest symptoms, first 4 weeks of illnessFatigue 65 (84·4%) of 77Headache 60 (77·9%) of 77Anosmia 60 (77·9%) of 77Symptoms for at least 5625 (1·8%) of 1379 childrenInterpretationCOVID-19 in children is usually of short duration with low symptom burdenSome children with COVID-19 experience prolonged illness durationSymptom burden did not increase with timeMost recovered by day 56 Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
Post-Vaccination Syndrome: Uploaded 19-11-23A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization https://www.medrxiv.org/content/10.1101/2023.11.09.23298266v1.full.pdfYale Listen to Immune, Symptom and Treatment Experiences Now (LISTEN) Study (online)https://medicine.yale.edu/ycci/listen-study/LISTEN study, approved by Yale University Institutional Review BoardIntroductionA chronic post-vaccination syndrome (PVS) after covid-19 vaccination has been reported but has yet to be well characterized.A chronic syndrome with symptoms that begin soon after vaccinationMethodsPeople who joined, May 2022 to July 2023N = 241 individuals, (211 from the US)aged 18 and older,who self-reported PVS after covid-19 vaccination,Deep immune profiling is used for some individualsResultsMedian age of participants, 46 yearsAmong participants with PVS127 (55%) had received BNT162b2 [Pfizer-BioNTech]86 (37%) received the mRNA-1273 [Moderna]Time from index vaccination to symptom onsetMedian time, 3 days (IQR: 1 day to 8 days). Time from vaccination to symptom survey completion595 days (IQR: 417 to 661 days)Median Euro-QoL visual analogue scale score was 50 (IQR: 39 to 70). The five most common symptomsExercise intolerance (71%)Excessive fatigue (69%)Numbness (63%)Brain fog (63%)Neuropathy (63%)In the week before survey completion(Experienced at least once in the week)Feeling unease (93%)Fearfulness (82%)Overwhelmed by worries (81%)Feelings of helplessness (80%)Anxiety (76%)Depression (76%)Hopelessness (72%)Worthlessness (49%)Concerns related to living situations and food security were also prominent. Symptom Severity When asked to quantify symptom severity on their worst days,(0 representing a trivial illness and 100 unbearable condition)Participants reported a median severity of 80Interventions to treat their conditionParticipants reported a median of 20 (IQR: 13 to 30). Oral steroids, 116 (48% participants)Gabapentin, 61 (25%)Low-dose naltrexone, 48 (20%)I, 44 (18%)Propranolol, 27 (11%)Bronchodilators, 26 (11%)More than 500 additional treatments were reported by participantsLimiting exercise or exertionQuitting alcohol or caffeineHydration and increasing salt intakeIntermittent fasting ConclusionsIn this study, individuals who reported PVS after covid-19 vaccination had low health status, high symptom burden, and high psychosocial stress,despite trying many treatments. There is a need for continued investigation to understand and treat this condition. Looks like you can join, Kindred studyKindred is a community of patients, working with researchers to power more useful, impactful progress.https://www.kindred.hugo.health/research/listen-studyhttps://kindredapp.hugo.health/auth/login?ref=%2F Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
With Professor David Anderson. Link to order or download, Vitamin D and the Great Biology Reset, https://dgreatbiologyreset.com/Uploaded 25-02-25Professor David Anderson (retired endocrinologist) emphasizes the importance of vitamin D3, especially for those in northern locations where sunlight exposure is limited in winter. Vitamin D is primarily produced when skin is exposed to sunlight (UVB rays); Professor Anderson argues most people are deficient and should supplement year-round. According to Anderson, a blood level above 50 ng/ml (125 nmol/L in UK units) is necessary for proper immune function and to protect against various diseases. Professor Anderson claims that vaccinations deplete vitamin D levels, particularly the "reservoir form" (calcifediol), and he and his wife take supplements to counteract this effect. The professor takes 100,000 units of vitamin D3 monthly (via oil-based solution) and personally takes either daily supplements (5,000-10,000 units) or calcifediol weekly, Overweight individuals may need higher doses and should titrate with blood levels under their doctors. Anderson and co-author David Grimes have published books on vitamin D deficiency and COVID-19, available as free PDF downloads from their website. He claims vitamin D is protective against some cancers, assists brain repair after strokes, and is linked to preventing numerous other health conditions. Anderson expresses concerns about pharmaceutical companies being opposed to vitamin D supplementation, alleging they profit from keeping people vitamin D deficient. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices